U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Collaborating Centre for Cancer (UK). Bladder Cancer: Diagnosis and Management. London: National Institute for Health and Care Excellence (NICE); 2015 Feb. (NICE Guideline, No. 2.)

Cover of Bladder Cancer

Bladder Cancer: Diagnosis and Management.

Show details

Key research recommendations

  • What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer?
  • Is primary radical cystectomy more effective than primary intravesical BCG in high-risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes?
  • In people with high-risk non-muscle-invasive bladder cancer, are these follow-up regimens equally effective in terms of identification of progression, cost effectiveness and health-related quality of life?
    • Cystoscopic follow-up at 3, 6, 12, 18, 24, 36 and 48 months, and then annually, interspersed with non-invasive urinary tests.
    • Cystoscopic follow-up at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 months, and then annually thereafter.
  • In patients with muscle-invasive bladder cancer suitable for radical treatment, does the use of biomarkers enable patients to select more effective treatment, and improve their outcomes compared with treatment selected without biomarkers?
  • Is symptom-based review as effective as scheduled follow-up for people treated with radical cystectomy or radical radiotherapy for organ-confined muscle-invasive bladder cancer? Outcomes of interest are overall survival, health-related quality of life, resource use and cost.
Copyright © National Collaborating Centre for Cancer.
Bookshelf ID: NBK356311

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...